Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q2 2019 · 10-Q
Revenue$895.78K$895.78K+264.9% vs Q2 2018 Net Income-$903.65K-$903.65KN/M vs Q2 2018 EPS Diluted-$0.30-$0.30N/M vs Q2 2018 Operating Income-$912,102N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-101.8%+3606.4 pt vs Q2 2018
Net margin-100.9%−146.2 pt vs Q2 2018
ended Jun 30, 2019 · filed Jul 17, 2019 · 17 d after period end